$FATE
Fate Therapeutics Inc

2020 Q3 Form 10-Q Financial Statement

#000156459020051301 Filed on November 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q3 2019 Q2
Revenue $7.558M $2.429M $2.817M
YoY Change 211.16% 136.74% 174.29%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.350M $6.350M $5.270M
YoY Change 31.5% 55.64% 37.96%
% of Gross Profit
Research & Development $30.69M $23.20M $21.63M
YoY Change 32.29% 70.14% 28.63%
% of Gross Profit
Depreciation & Amortization $780.0K $590.0K $540.0K
YoY Change 32.2% 90.32% 92.86%
% of Gross Profit
Operating Expenses $39.05M $29.55M $26.90M
YoY Change 32.14% 66.77% 30.38%
Operating Profit -$31.49M -$27.12M -$24.08M
YoY Change 16.11% 62.47% 22.85%
Interest Expense -$27.20M $510.0K $409.0K
YoY Change -5433.33% 18.88% -3.76%
% of Operating Profit
Other Income/Expense, Net -$27.20M $606.0K
YoY Change -1336.73%
Pretax Income -$58.68M -$26.61M -$23.48M
YoY Change 120.52% 58.58% 19.49%
Income Tax
% Of Pretax Income
Net Earnings -$58.68M -$26.61M -$23.48M
YoY Change 120.54% 58.56% 19.46%
Net Earnings / Revenue -776.45% -1095.47% -833.44%
Basic Earnings Per Share
Diluted Earnings Per Share -$675.3K -$397.6K -$360.1K
COMMON SHARES
Basic Shares Outstanding 65.19M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $488.8M $302.8M $162.0M
YoY Change 61.43% 43.37% 107.69%
Cash & Equivalents $349.1M $249.6M $71.44M
Short-Term Investments $139.7M $53.20M $90.60M
Other Short-Term Assets $4.700M $2.800M $3.200M
YoY Change 67.86% 27.27% 60.0%
Inventory
Prepaid Expenses
Receivables $3.200M $0.00 $0.00
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $496.8M $305.6M $165.2M
YoY Change 62.57% 42.87% 106.38%
LONG-TERM ASSETS
Property, Plant & Equipment $87.80M $9.653M $9.225M
YoY Change 809.56% 154.03% 218.76%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $13.20M
YoY Change
Other Assets $15.20M $9.000K $200.0K
YoY Change 168788.89% -95.5% 0.0%
Total Long-Term Assets $129.6M $34.61M $34.70M
YoY Change 274.49% 467.33% 1011.79%
TOTAL ASSETS
Total Short-Term Assets $496.8M $305.6M $165.2M
Total Long-Term Assets $129.6M $34.61M $34.70M
Total Assets $626.4M $340.2M $199.9M
YoY Change 84.12% 54.64% 140.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.700M $5.715M $5.410M
YoY Change -35.26% 9.9% 54.13%
Accrued Expenses $14.78M $13.84M $9.834M
YoY Change 6.78% 44.2% 17.41%
Deferred Revenue $3.367M $5.049M
YoY Change 3.6% 184.29%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $13.93M $5.447M
YoY Change 322.18% 170.86%
Total Short-Term Liabilities $54.20M $40.60M $29.42M
YoY Change 33.5% 78.83% 80.78%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $9.469M
YoY Change -100.0% -26.23%
Other Long-Term Liabilities $147.9M $31.60M $33.50M
YoY Change 368.04% 167.8% 1422.73%
Total Long-Term Liabilities $147.9M $31.60M $9.469M
YoY Change 368.04% 35.04% -26.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $54.20M $40.60M $29.42M
Total Long-Term Liabilities $147.9M $31.60M $9.469M
Total Liabilities $202.1M $72.20M $38.89M
YoY Change 179.92% 56.96% 33.6%
SHAREHOLDERS EQUITY
Retained Earnings -$503.8M -$328.6M
YoY Change 30.11%
Common Stock $87.00K $65.00K
YoY Change 22.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $424.4M $268.0M $127.5M
YoY Change
Total Liabilities & Shareholders Equity $626.4M $340.2M $199.9M
YoY Change 84.14% 54.64% 140.37%

Cashflow Statement

Concept 2020 Q3 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income -$58.68M -$26.61M -$23.48M
YoY Change 120.54% 58.56% 19.46%
Depreciation, Depletion And Amortization $780.0K $590.0K $540.0K
YoY Change 32.2% 90.32% 92.86%
Cash From Operating Activities -$30.74M -$19.84M -$20.31M
YoY Change 54.94% 457.3% 76.3%
INVESTING ACTIVITIES
Capital Expenditures -$950.0K -$1.270M -$1.790M
YoY Change -25.2% 73.97% 539.29%
Acquisitions
YoY Change
Other Investing Activities -$53.19M $37.55M -$90.18M
YoY Change -241.65% 168.21% -744.14%
Cash From Investing Activities -$54.14M $36.28M -$91.97M
YoY Change -249.23% 173.4% -770.34%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 930.0K 161.7M 690.0K
YoY Change -99.42% 17.71% -40.0%
NET CHANGE
Cash From Operating Activities -30.74M -19.84M -20.31M
Cash From Investing Activities -54.14M 36.28M -91.97M
Cash From Financing Activities 930.0K 161.7M 690.0K
Net Change In Cash -83.95M 178.1M -111.6M
YoY Change -147.13% 21.12% -3431.04%
FREE CASH FLOW
Cash From Operating Activities -$30.74M -$19.84M -$20.31M
Capital Expenditures -$950.0K -$1.270M -$1.790M
Free Cash Flow -$29.79M -$18.57M -$18.52M
YoY Change 60.42% 556.18% 64.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 fate Short Term Investments And Related Maturity Receivables
ShortTermInvestmentsAndRelatedMaturityReceivables
121613000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7878000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15538000
us-gaap Operating Income Loss
OperatingIncomeLoss
-71649000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3016000
fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
27644000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1802000
us-gaap Net Income Loss
NetIncomeLoss
-69847000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
53000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-69794000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.06
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
87004686
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
87004686
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75730260
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75730260
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
87000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
54195000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
83156000
CY2020Q3 fate Stock Price Appreciation Milestones Liabilities Non Current
StockPriceAppreciationMilestonesLiabilitiesNonCurrent
14559000
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
3000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
76000
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
927784000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
628200000
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
312000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
22000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-503821000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-383545000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
424365000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
244756000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
626443000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
302274000
us-gaap Profit Loss
ProfitLoss
-69847000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1570000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12827000
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
433000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
59937000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3243000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-2626000
fate Increase Decrease In Right Of Use Assets And Lease Liabilities Net
IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet
5904000
CY2020Q3 fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
27644000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
65695188
fate Increase Decrease In Fair Value Of Stock Price Appreciation Milestones
IncreaseDecreaseInFairValueOfStockPriceAppreciationMilestones
27644000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12204000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
92337000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
106182000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
99950000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
64050000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
50000000
fate Proceeds From Issuance Of Common Stock In Connection With Collaboration Agreement
ProceedsFromIssuanceOfCommonStockInConnectionWithCollaborationAgreement
33934000
fate Proceeds From Cirm Award
ProceedsFromCIRMAward
440000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
1000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
277928000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
163651000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
264316000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
59074000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
364357000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
249815000
us-gaap Interest Paid Net
InterestPaidNet
938000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1183000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
804000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
48099000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
7705000
CY2019Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
227000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
249815000
us-gaap Net Income Loss
NetIncomeLoss
-120300000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26100000
us-gaap Net Income Loss
NetIncomeLoss
-69800000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24000000.0
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s unaudited condensed consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (U.S. GAAP). The preparation of the Company’s unaudited condensed consolidated financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s unaudited condensed consolidated financial statements and accompanying notes. The most significant estimates and assumptions in the Company’s unaudited condensed consolidated financial statements relate to its contracts containing leases, accrued expenses and the estimated total costs expected to be incurred under the Company’s collaboration agreements. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p>
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
349130000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
249588000
CY2020Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
15227000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
364357000
CY2020Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
15200000
CY2019Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
200000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-58700000
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26100000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-26600000
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24000000.0
fate Period To Treat Award As Grant If Award Not Treated As Loan
PeriodToTreatAwardAsGrantIfAwardNotTreatedAsLoan
P10Y
CY2020Q3 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2019Q3 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2019Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2020Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2020Q3 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2019Q3 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2019Q3 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2020Q3 us-gaap Other Than Temporary Impairment Credit Losses Recognized In Earnings Credit Losses On Debt Securities Held
OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCreditLossesOnDebtSecuritiesHeld
0
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
608000
CY2019Q3 us-gaap Variable Lease Cost
VariableLeaseCost
589000
us-gaap Variable Lease Cost
VariableLeaseCost
1633000
us-gaap Variable Lease Cost
VariableLeaseCost
1743000
CY2019Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
400000
us-gaap Interest Expense Debt
InterestExpenseDebt
1200000
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
These leases have terms varying from one to approximately sixteen years, with renewal options of up to ten years
CY2020Q3 us-gaap Share Price
SharePrice
39.97
CY2020Q3 us-gaap Share Price
SharePrice
39.97
CY2020Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2020Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2020Q3 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2020Q3 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
6843000
CY2019Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
5329000
CY2020Q3 fate Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
4126000
CY2019Q4 fate Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
5976000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3813000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3392000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14782000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14697000
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P13Y4M24D
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.084
CY2020Q3 us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
3039000
CY2019Q3 us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
945000
us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
8948000
us-gaap Straight Line Rent Adjustments
StraightLineRentAdjustments
2836000
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
3647000
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1534000
us-gaap Operating Lease Cost
OperatingLeaseCost
10581000
us-gaap Operating Lease Cost
OperatingLeaseCost
4579000
CY2020Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
200000
CY2019Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
400000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
900000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
600000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1079000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
9741000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
12610000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
12988000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
13378000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
13779000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
130447000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
194022000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
87171000
CY2020Q3 fate Amounts Associated With Tenant Improvement Allowance Not Yet Utilized
AmountsAssociatedWithTenantImprovementAllowanceNotYetUtilized
21365000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
85486000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7843000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4573000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21992000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12827000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
244756000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
949000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6913000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
120000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-33520000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
219218000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2548000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
188791000
CY2020Q2 fate Common Stock Issued During Period Value Private Placement1
CommonStockIssuedDuringPeriodValuePrivatePlacement1
49975000
CY2020Q2 fate Stock Issued During Period Value In Connection With Collaboration Agreement
StockIssuedDuringPeriodValueInConnectionWithCollaborationAgreement
33934000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
481000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-28072000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
474111000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1413000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7843000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-7000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-311000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-58684000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
424365000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
160469000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1258000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3868000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-19760000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
145837000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
688000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4386000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
93000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-23478000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
127526000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
163000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4573000
CY2019Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
162431000
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-42000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-26609000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
268042000

Files In Submission

Name View Source Status
0001564590-20-051301-index-headers.html Edgar Link pending
0001564590-20-051301-index.html Edgar Link pending
0001564590-20-051301.txt Edgar Link pending
0001564590-20-051301-xbrl.zip Edgar Link pending
fate-10q_20200930.htm Edgar Link pending
fate-10q_20200930_htm.xml Edgar Link completed
fate-20200930.xsd Edgar Link pending
fate-20200930_cal.xml Edgar Link unprocessable
fate-20200930_def.xml Edgar Link unprocessable
fate-20200930_lab.xml Edgar Link unprocessable
fate-20200930_pre.xml Edgar Link unprocessable
fate-ex311_6.htm Edgar Link pending
fate-ex312_85.htm Edgar Link pending
fate-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending